Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
B7-H3-CAR T cells(St. Jude Children's Research Hospital) in Diffuse midline glioma, point mutation K27M in histone H3: NCT05835687 Clinical Landscape Report 2026
16 October 2026
NCT05835687 clinical landscape for Diffuse midline glioma, point mutation K27M in histone H3: endpoints, sponsor, phase, geography, readouts, asset context a…
9 min read
OMX-0407 in Solid tumor: NCT05826600 Clinical Landscape Report 2026
16 October 2026
NCT05826600 clinical landscape for Solid tumor: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Aldesleukin in Triple Negative Breast Cancer: NCT05821686 Clinical Landscape Report 2026
16 October 2026
NCT05821686 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Eribulin mesylate in Hepatocellular Carcinoma: NCT05824975 Clinical Landscape Report 2026
16 October 2026
NCT05824975 clinical landscape for Hepatocellular Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Futibatinib in Endometrial Carcinoma: NCT05827614 Clinical Landscape Report 2026
16 October 2026
NCT05827614 clinical landscape for Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Serplulimab in Metastatic Clear Cell Renal Cell Carcinoma: NCT05831891 Clinical Landscape Report 2026
16 October 2026
NCT05831891 clinical landscape for Metastatic Clear Cell Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development…
9 min read
Nivolumab in Renal Cell Carcinoma: NCT05846646 Clinical Landscape Report 2026
16 October 2026
NCT05846646 clinical landscape for Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Temozolomide in Diffuse midline glioma, point mutation K27M in histone H3: NCT05843253 Clinical Landscape Report 2026
16 October 2026
NCT05843253 clinical landscape for Diffuse midline glioma, point mutation K27M in histone H3: endpoints, sponsor, phase, geography, readouts, asset context a…
9 min read
Tocilizumab in ER-positive/HER2-negative Breast Cancer: NCT05846789 Clinical Landscape Report 2026
16 October 2026
NCT05846789 clinical landscape for ER-positive/HER2-negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development whi…
9 min read
Cyclophosphamide in Germline BRCA-mutated, HER2-negative metastatic breast cancer: NCT05834582 Clinical Landscape Report 2026
16 October 2026
NCT05834582 clinical landscape for Germline BRCA-mutated, HER2-negative metastatic breast cancer: endpoints, sponsor, phase, geography, readouts, asset conte…
9 min read
BPI-452080 in Von Hippel-Lindau Disease: NCT05843305 Clinical Landscape Report 2026
16 October 2026
NCT05843305 clinical landscape for Von Hippel-Lindau Disease: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
ADU-1805 in Endometrial Carcinoma: NCT05856981 Clinical Landscape Report 2026
16 October 2026
NCT05856981 clinical landscape for Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.